October 15, 2004Journal of Medicinal ChemistryOpen Access

Design, Synthesis, and Biological Evaluation of the First Selective Nonpeptide AT2 Receptor Agonist

View Full Paper

Ask AI

Bookmark

Population

Sprague-Dawley rats, anesthetized spontaneously hypertensive rats, and neurite cells

Design

Preclinical

Authors

YWYiqian WanSun Yat-sen University CWCharlotta WallinderUppsala University BPBianca PlouffeQueen's University Belfast

Discussion

Member takes

Implication

Enables detailed AT2 functional studies; leaves open translation to human hypertension therapy.

Structured PICO

Population

Sprague-Dawley rats, anesthetized spontaneously hypertensive rats, and neurite cells

Intervention

Compound 21 (selective nonpeptide AT2 receptor agonist)

Outcome

Receptor binding affinity (Ki), oral bioavailability, half-life, neurite cell outgrowth, p42/p44(mapk) stimulation, duodenal alkaline secretion, and mean arterial blood pressuresurrogate

The synthesis of Compound 21 provides the first druglike selective nonpeptide AT2 receptor agonist, enabling detailed functional studies of the AT2 receptor.

Cite This Study

Wan et al. (2004) studied this question.

synapsesocial.com/papers/6a7ca521398814c3397ccdeb https://doi.org/10.1021/jm049715t

View Full Paper

Ask AI

Bookmark

Design, Synthesis, and Biological Evaluation of the First Selective Nonpeptide AT2 Receptor Agonist

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Design, Synthesis, and Biological Evaluation of the First Selective Nonpeptide AT2 Receptor Agonist

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider